anti-IL-36γ (human), mAb (Jussy-1)
|Synonyms||Interleukin-36γ; Interleukin-1 Family Member 9; IL-1F9|
|Product Type||Monoclonal Antibody|
|Source/Host||Purified from concentrated hybridoma tissue culture supernatant.|
|Immunogen/Antigen||Recombinant human IL-36γ.|
Western Blot: (1:1'000)
Recognizes human IL-36γ.
|Purity Detail||Protein A affinity purified.|
|Formulation||Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.|
|Isotype Negative Control|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
|Use/Stability||Stable for at least 1 year after receipt when stored at -20°C.|
|Product Specification Sheet|
IL-36α (IL-1F6), IL-36β (IL-1F8) and IL-36γ (IL-1F9) bind to IL-36R (IL-1Rrp2) and IL-1RAcP, activating similar intracellular signals as IL-1 and are inhibited by IL-36Ra. The expression of IL-36 cytokines has been shown to occur at different sites including the lung and skin and can be derived from diverse cell types including keratinocytes, bronchial epithelium as well as macrophages, monocytes and different T cell subsets. IL-36 family members induce the production of proinflammatory cytokines, including IL-12, IL-1β, IL-6, TNF-α and IL-23 in BMDC and CD4 T cells, thus promoting neutrophil influx, dendritic cell (DC) activation, polarization of T helper type 1 (Th1) and IL-17-producing T cells (αβ T cells and γδ T cells) and keratinocyte proliferation. These cytokines may represent potential targets for immune-mediated inflammatory conditions or, alternatively, could be used as adjuvants in vaccination. IL-36γ is also induced in the lung in various models of asthma and can be produced by bronchial epithelial cells in response to viral infection, smoke or inflammatory cytokines.